Lydia Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lydia Chen has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Fanny Chapelin
Shu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA
1 shared publication - Jacob Joel Hoenig
University of California San Diego
1 shared publication - Xiaohan Yang
Shu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA
1 shared publication - Yu Ping
Shu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, La Jolla, CA 92093, USA
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (11) , 691
Mapping Therapeutic Regulatory T Cell Fate with MRI: Current Strategies and Translational Outlook
Adoptive cell therapies, and more specifically, regulatory T cell (Treg) therapies, have shown significant therapeutic promise across multiple immune-mediated diseases including graft-versus-host disease (GvHD), solid organ transplant (SOT) rejection, and autoimmune diseases. One key challenge is the lack of insight into the biodistribution and fate of adoptively transferred T cells and Tregs in living organisms. These uncertainties delay progress on establishing optimal dosage(s), infusion timing and route, as well as investigations into off-target effects. Magnetic resonance imaging (MRI) cell tracking is particularly beneficial in this setting because it enables real-time, deep-tissue coverage without ionizing radiation. In this review, we compare existing MRI T cell tracking strategies using iron oxide particles and fluorinated agents. We describe preclinical and clinical applications of MRI for cell therapy tracking and provide a perspective on the potential impact on the field.
- 1 June 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (11) , 691
Open AccessMapping Therapeutic Regulatory T Cell Fate with MRI: Current Strategies and Translational Outlook
Adoptive cell therapies, and more specifically, regulatory T cell (Treg) therapies, have shown significant therapeutic promise across multiple immune-mediated diseases including graft-versus-host disease (GvHD), solid organ transplant (SOT) rejection, and autoimmune diseases. One key challenge is the lack of insight into the biodistribution and fate of adoptively transferred T cells and Tregs in living organisms. These uncertainties delay progress on establishing optimal dosage(s), infusion timing and route, as well as investigations into off-target effects. Magnetic resonance imaging (MRI) cell tracking is particularly beneficial in this setting because it enables real-time, deep-tissue coverage without ionizing radiation. In this review, we compare existing MRI T cell tracking strategies using iron oxide particles and fluorinated agents. We describe preclinical and clinical applications of MRI for cell therapy tracking and provide a perspective on the potential impact on the field.